Literature DB >> 25862396

Perspectives on the design of clinical trials for targeted therapies and immunotherapy in veterinary oncology.

Laura Marconato1, Paolo Buracco2, Luca Aresu3.   

Abstract

The field of oncology research has undergone major changes in recent years. Progress in molecular and cellular biology has led to a greater understanding of the cellular pathways and mechanisms of cell proliferation and tissue invasion associated with cancer. New classes of cancer therapies are becoming available or are in development but these new agents require a paradigm shift in the design of oncology clinical trials. This review provides an overview of clinical trial designs for the development of tumour vaccines and targeted therapeutic agents. In addition, some of the successes, limitations and challenges of these trials are discussed, with a special emphasis on the difficulties and particularities that are encountered in veterinary medicine compared to similar work in human patients.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clinical trials; Endpoints; Immunotherapy; Oncology; Targeted therapy; Veterinary

Mesh:

Substances:

Year:  2015        PMID: 25862396     DOI: 10.1016/j.tvjl.2015.02.020

Source DB:  PubMed          Journal:  Vet J        ISSN: 1090-0233            Impact factor:   2.688


  2 in total

1.  Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination.

Authors:  L A Piras; F Riccardo; S Iussich; L Maniscalco; F Gattino; M Martano; E Morello; S Lorda Mayayo; V Rolih; F Garavaglia; R De Maria; E Lardone; F Collivignarelli; D Mignacca; D Giacobino; S Ferrone; F Cavallo; P Buracco
Journal:  Vet Comp Oncol       Date:  2016-05-04       Impact factor: 2.613

2.  Conduct, Oversight, and Ethical Considerations of Clinical Trials in Companion Animals with Cancer: Report of a Workshop on Best Practice Recommendations.

Authors:  R Page; P Baneux; D Vail; L Duda; P Olson; L Anestidou; N Dybdal; G Golab; W Shelton; M Salgaller; C Hardy
Journal:  J Vet Intern Med       Date:  2016-03-07       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.